Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 12/20 | 0.62 |
| ▸ | CA1 | P00915 | 8/20 | 0.62 |
| ▸ | NAMPT | P43490 | 4/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5441326 | 0.89 | MAOB (0.79) | MAOBNAMPTNR1H4 | |
| SCHEMBL5410792 | 0.89 | MAOB (0.65) | MAOBNAMPTCYP2C9EPHX2NR1H4 | |
| SCHEMBL5417278 | 0.86 | MAOB (0.71) | MAOBNAMPT | |
| SCHEMBL5409324 | 0.84 | MAOB (0.72) | MAOBNAMPTEPHX2 | |
| SCHEMBL5406113 | 0.83 | MAOB (0.71) | MAOBNAMPT | |
| SCHEMBL5413102 | 0.83 | MAOB (0.71) | MAOBNAMPT | |
| SCHEMBL5179231 | 0.83 | MAOB (0.70) | MAOBNAMPTNR1H4 | |
| SCHEMBL12466902 | 0.82 | NAMPT (0.77) | MAOBNAMPT | |
| SCHEMBL5407810 | 0.82 | MAOB (0.69) | MAOBCA2 | |
| SCHEMBL5413383 | 0.82 | MAOB (0.65) | MAOBCA2NAMPTHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | MAOB 2025/4885CA2 1390/4885CA1 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.